Skip to main content

Table 1 Population and cancer characteristics by pre-diagnostic colonoscopy among colorectal cancer patients registered in 2003–2013, South Australia (n = 12,906)

From: Pre-diagnostic colonoscopies reduce cancer mortality - results from linked population-based data in South Australia

  No colonoscopy n = 8194 Colonoscopy n = 4712 Total n = 12,906 P value
Mean age (SD) at diagnosis (years) 69.4 (13.5) 71.5 (12.0) 70.2 (13.0) < 0.001
Age at diagnosis (years)     < 0.001**
  < 60 1843 (22.5%) 764 (16.2%) 2607 (20.0%)  
 60–69 2025 (24.7%) 1067 (22.7%) 3092 (24.0%)  
 70–79 2191 (26.8%) 1554 (33.0%) 3745 (29.0%)  
  > 80 2129 (26.0%) 1326 (28.2%) 3455 (26.8%)  
Sex     0.043*
 Male 4365 (54.7%) 2447 (52.8%) 6812 (54.0%)  
 Female 3621 (45.3%) 2188 (47.1%) 5809 (46.0%)  
Country of birth     < 0.001*
 Australia & NZ 5486 (68.9%) 3206 (70.2%) 8692 (69.4%)  
 Europe 1931 (24.3%) 1153 (25.3%) 3084 (24.6%)  
 North Africa/Middle East 18 (0.2%) 16 (0.4%) 34 (0.3%)  
 Asia & Pacific Islands 114 (1.5%) 52 (1.2%) 166 (1.4%)  
 Americas 31 (0.4%) 8 (0.2%) 39 (0.3%)  
 Africa (other) 370 (4.7%) 130 (2.9%) 500 (4.0%)  
Indigenous     0.100*
 No 7596 (99.8%) 4476 (99.6%) 12,072 (99.7%)  
 Yes 19 (0.3%) 19 (0.4%) 38 (0.3%)  
Remoteness     < 0.001**
 Major city 6022 (73.5%) 3174 (67.4%) 9196 (71.3%)  
 Inner regional 893 (10.9%) 508 (10.8%) 1401 (10.9%)  
 Outer regional and remote 1278 (15.6%) 1029 (21.8%) 2307 (17.9%)  
SES disadvantage quintile     < 0.001**
 1st (most disadvantage) 1884 (23.0%) 1327 (28.2%) 3211 (24.9%)  
 2nd 1813 (22.1%) 1058 (22.5%) 2871 (22.3%)  
 3rd 1545 (18.9) 936 (19.9%) 2481 (19.3%)  
 4th 1615 (19.7%) 809 (17.2%) 2424 (18.8%)  
 5th (least disadvantage) 1332 (16.3%) 572 (12.2%) 1904 (14.8%)  
Local Health Network     < 0.001*
 Country Health SA 2424 (29.6%) 1689 (35.9%) 4113 (31.9%)  
 Central Adelaide 2507 (30.6%) 1269 (26.9%) 3776 (29.3%)  
 Northern Adelaide 1628 (19.9%) 872 (18.5%) 2500 (19.4%)  
 Southern Adelaide 1634 (19.9%) 880 (18.7%) 2514 (19.5%)  
Median (IQR) of years survived on Dec 31st 2013 2.7 (0.9–5.5) 3.0 (1.1–6.3) 2.8 (1.0–5.7) < 0.001
Cancer staging (max spread)     < 0.001**
 Local 2001 (42.9%) 1479 (49.8%) 3480 (45.6%)  
 Regional 1556 (33.4%) 897 (30.2%) 2453 (32.1%)  
 Distant 1108 (23.8%) 595 (20.0%) 1703 (22.3%)  
% cancer-specific survival by time from diagnosis     < 0.001***
 At 1 year 84.5% 86.8% 85.5%  
 At 3 year 71.0% 74.6% 72.3%  
 At 5 year 64.6% 69.4% 66.0%  
  1. *p from Fisher’s exact or Chi-square test; **p from Mann-Whitney U test; ***p from log-rank test for equality of survivor functions; note - cell totals < overall totals due to missing records